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Inflammatory bowel diseases (IBD) are chronic relapsing intestinal disorders
characterized by up-regulation of pro-inflammatory cytokines followed by invasion
of immune cells to the intestinal lamina propria. Standard therapies consist of anti-
inflammatory or immunosuppressive drugs. Since clinical efficiency is not satisfactory
and the established drugs have massive side effects, new strategies to treat IBD are
required. Herein, we investigate the protective effect of the fixed combination herbal
preparations STW5 and STW5-II and the contribution of the corresponding single
components in an in vitro inflammation model. The normal human colon epithelial
cell line, NCM460, was treated with STW5, STW5-II or their single components for
4 h followed by experimental conditions comparable to induction of colitis. A pro-
inflammatory cytokine cocktail consisting of TNF-α, IL-β, and IFN-γ was used to simulate
inflammatory stimuli normally caused by immune cells. The effects on NCM460 cells
were investigated by enzyme-linked immunoassay and Proteome Profiler©R . Levels of IP-
10, MCP-1, I-TAC, Groα, and IL-8 were elevated in chemokine-treated cells compared
to untreated cells, but significantly reduced upon pretreatment with STW5 or STW5-
II. However, the single compounds revealed only little effects on protein expression.
Furthermore, we investigated the effect of both combination preparations on pro-
inflammatory transcription factors of the STAT family using Western blot. In addition,
we tested the effects on upstream MAPK p38. Both, STW5 and STW5-II did not show
any effect on MAPK p38, but were effective in reducing phosphorylated levels of STAT1.
In conclusion, both combination preparations act in an anti-inflammatory manner by
influencing cytokine secretion via reduced activity of the JAK/STAT1 pathway. Relevant
differences between STW5 and STW5-II were not found indicating similar efficacies.
Keywords: Inflammatory bowel disease, Phytotherapy, Proteomics
Abbreviations: CD, Crohn’s disease; CM, cytokine mixture; ELISA, enzyme-linked immunoassay; IBD, inflammatory bowel
disease; IFN, interferon; IL, interleukin; PMA, phorbol 12-myristate 13-acetate; TNF, tumor necrosis factor; UC, ulcerative
colitis.
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INTRODUCTION
Crohn’s disease and UC are the most common forms of IBD with
high incidence and prevalence in western civilizations (Karlinger
et al., 2000). Both are characterized by a dysregulated balance
between pro- and anti-inflammatory processes in the intestinal
tract leading to chronic inflammation (Vecchi Brumatti et al.,
2014). Although the etiology of IBD remains unclear, genetic,
and environmental factors have been implicated in disease
pathogenesis (Ferguson et al., 2007; Xavier and Podolsky, 2007).
Medicinal standard therapies comprise anti-inflammatory
agents such as 5-aminosalicylate, glucocorticoids, immuno-
suppressant drugs, or therapeutic antibodies (Abraham and Cho,
2009; Danese and Fiocchi, 2011). Diagnosis of IBD is based
on symptoms and endoscopic evaluation (Kugathasan et al.,
2003). The intestinal inflammation is often monitored by clinical
indices and invasive techniques (Crama-Bohbouth et al., 1989;
Langhorst et al., 2008). Cytokines may act as surrogate markers,
since elevated levels have been found in the intestinal mucosa of
patients with IBD.
Cytokines are biologically active compounds involved in
immune reactions and can be classified as being pro- or anti-
inflammatory. They are produced by both resident and migrating
cells. A subset of cytokines, called chemokines, is responsible for
the migration of immune cells to the site of inflammation (Calixto
et al., 2004). Targeting cytokine pathways is a promising target for
treating IBD and is already established in the case of anti-tumor
necrosis factor-alpha (TNF-α) antibodies. Side effects associated
with these therapies, e.g., high risk of infections (Khanna and
Feagan, 2015) underscore the need of novel improved treatment
strategies.
Some natural products showed promising activities in the
treatment of intestinal inflammation (Schneider et al., 2014),
and could present an additional treatment option for IBD.
STW5 (Iberogast R©) consists of a fixed combination of nine
hydro-alcoholic extracts of medicinal plants which have been
traditionally used in Europe to treat diverse gastrointestinal
illnesses. It is a well-tolerated herbal medicinal product, clinically
used for the treatment of functional dyspepsia and irritable bowel
syndrome (Holtmann et al., 2004; Allescher and Wagner, 2007)
and shown to be effective in gastroesophageal reflux disease
models (Abdel-Aziz et al., 2010, 2015; Patrick, 2011). In animal
models of UC, STW5 was able to reduce inflammatory markers
and histological changes (Michael et al., 2012; Wadie et al., 2012).
The aim of the present study was to investigate the
mechanisms of action of STW5 (fixed combination of nine herbal
extracts; Iberogast R©), the investigational preparation STW5-II
(fixed combination of six herbal extracts, lacking three extracts
of STW5), and their corresponding single extracts in terms of
cytokine secretion from inflamed intestinal cells.
MATERIALS AND METHODS
Substances
STW5 was provided in the form of lyophylisates by Steigerwald
Arzneimittelwerk GmbH (Darmstadt, Germany). The
preparation consists of the 50% (v/v) hydroethanolic fresh
plant extract of Iberis amara L. (Brassicaceae) whole plants
and the 30% hydroethanolic extracts of dried Melissa officinalis
L. (Lamiaceae) leaves, Matricaria chamomilla (Compositae)
flowers, Carum carvi L. (Apiaceae) fruits, Mentha piperita L.
(Lamiaceae), Angelica archangelica L. (Apiaceae) roots, Silybum
marianum (L.) Gaertn. (Compositae) fruits, Chelidonium majus
L. (Papaveraceae) herbs, and Glycyrrhiza glabra L. (Leguminosae)
roots. STW5-II (investigational mixture) and the single extracts
were also provided as lyophylisates (Table 1). The preparations
and their single extracts are well characterized according to
validated analytical methods. They belong according to the
guidelines of the European Medicines Agency to “other herbal
substances.” The extraction processes as well as the quality
controls were previously described in detail (Kroll and Cordes,
2006; Allam et al., 2015). Briefly, the extracts were produced
and their quality controlled according to Good Manufacturing
Practice and Good Agricultural Practice of Medicinal and
Aromatic Plants (cited and outlined in Kroll and Cordes, 2006).
The quality of each extract is tested according to individual
specifications, among which is the identity of the used drug
(chromatographic fingerprint) and the content of marker
substances (Allam et al., 2015) within a defined range, as
measured by high performance liquid chromatography or
gas-liquid chromatography.
Lyophilisates were freshly re-suspended in Dulbecco’s
modified eagle medium (DMEM; Life Technology, Darmstadt,
Germany) supplemented with 1% non-essential amino acids
(NEAA, Life Technology, Darmstadt, Germany) shortly
before use.
Cell Culture
NCM460 cells were purchased from INCELL Corporation (San
Antonio, TX, USA) and cultured in M3 media (San Antonio,
TX, USA) supplemented with 10% FBS (fetal bovine serum),
100 U/ml penicillin and 100 µg/ml streptomycin at 37◦C in a
95% humidified atmosphere with 5% CO2. Cells were passaged
at pre-confluent densities using 0.05% trypsin and 0.5 mm EDTA
(Invitrogen, Karlsbad, Germany).
Cell Viability Assay
The cytotoxic effects of the test extracts against NCM460 were
assessed after 24 h using a resazurin reduction assay (RRA)
according to O’Brien et al. (2000). Cells were seeded in 96-well
plates at a density of 10,000 cells per well in 0.1 ml medium. After
24 h cultivation, cells were treated with different concentrations
of the plant extracts or DMEM (negative control). Following
24 h incubation at 37◦C and 5% CO2, 20 µl resazurin working
solution (0.01% w/v) were added per well. After another 4 h
incubation, the resazurin solution was analyzed by fluorometry
using the Infinite M2000 ProTM plate reader (excitation at 544 nm
and emission at 590 nm, Tecan, Crailsheim, Germany). The
cytotoxicity of the test extracts was evaluated by comparing values
of emission at 590 nm for the treated probes to normalized
medium controls. The mean absorbance for the negative control
(Medium) was normalized as 100%.
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TABLE 1 | Overview of used plant extracts: Composition of STW5 and STW5-II.
Code (batch number) Plant origin Drug-Extract ratio Concentrations (µl/ml) Content in STW5 Content in STW5-II
STW5 (430392) mixture – various proprietary –
STW5-II (141008) Investigational mixture – various proprietary –
STW6 (13187) Iberis amara L. 1:1.5–2.5 1,5 15% 15%
STW5 KII (13182) Mentha piperita L 1:2.5–3.5 1 5% 10%
STW5 KIII (13176) Matricaria chamomilla L. 1:2–4 3 20% 30%
STW5 KIV (13192) Glycyrrhiza glabra L. 1:2.5–3.5 1 10% 10%
STW5 KV (13175) Angelica archangelica L. 1:2.5–3.5 1 10% –
STW5 KVI (13188) Carum carvi L. 1:2.5–3.5 2 10% 20%
STW5 KVII (23033) Silybum marianum (L.) Gaertn. 1:2.5–3.5 1 10% –
STW5 KVIII (13195) Melissa officinalis L. 1:2.5–3.5 1,5 10% 15%
STW5 KIX (23044) Chelidonium majus L. 1:2.5–3.5 1 10% –
The used concentrations of the single components depend on the concentrations within STW5-II. In case of KV, KVII, and KIX concentrations of STW5 were used.
Proteome ProfilerTM Human Cytokine
Antibody Array
To evaluate anti-inflammatory effects of plant extracts on
NCM460 cells, the cytokine and chemokine production was
investigated using the ‘Human Cytokine Array Panel A’ array
system obtained from R&D Systems GmbH (Wiesbaden-
Nordenstadt, Germany). Following 3-days cultivation of
NCM460 cells in a 12 well plate under standard conditions,
medium was removed and cells were washed with PBS.
Cells were pre-treated with plant extracts for 4 h and
subsequently inflammation was induced for 24 h using a
human CM consisting of 10 ng/ml TNF-α, 5 ng/ml IL-1β,
and 10 ng/ml IFN-γ. After centrifugation, the supernatant
was collected and analyzed according to the manufacturer’s
instructions.
Enzyme-Linked Immunoassay
As the “Proteome ProfilerTM” delivers only semi-quantitative
data, enzyme-linked immunosorbent assays were performed
using DuoSet Kits from R&D Systems according to the
manufacturer’s instructions. Aliquots of 100 µl were pipetted
onto the plates coated with the capture antibody. Plates were
analyzed using the Infinite M2000 ProTM plate reader (Tecan) at
a wavelength of 450 nm.
HEK-Blue Reporter Cell Line
HEK293 cell lines stably expressing HEK-Blue-Null1 vector
for secreted alkaline phosphatase on a NF-κB promoter were
purchased from InvivoGen (San Diego, CA, USA). The cells
were cultured according to the manufacturer’s recommendations.
The cells were treated with varying concentrations of STW5 or
STW5-II for 4 h and then inflammation was induced with TNF-α
(10 ng/ml) for 24 h. NF-κB activation was spectrophotometrically
detected by measuring secreted embryonic alkaline phosphatase
at 630 nm upon Quanti Blue addition (InvivoGen, San Diego, CA,
USA). A known NF-κB inhibitor, MG-132 was used as positive
control (Zanotto-Filho et al., 2011).
Cell Extracts
NCM460 cells were seeded at 20,000 cells/cm2 in a 6-well plate
and grown for 3 days in RPMI media supplemented with 10%
FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin at 37◦C
in a 95% humidified atmosphere with 5% CO2. Medium was
removed and replaced with DMEM supplemented with 1%
FIGURE 1 | Cytotoxic effects of STW5 and STW5-II: NCM460 cells were treated with STW5 or STW5-II for 24 h. Cytotoxicity was measured by resazurin
assays by normalizing to untreated control.
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NEAA containing or not containing the STW extracts. After 4 h
incubation, the medium was removed and cells were induced for
various times with human CM consisting of 10 ng/ml TNF-α,
5 ng/ml IL-1β, and 10 ng/ml IFN-γ. Cells were washed with PBS,
incubated with cell lysis buffer (New England Biolabs) for 5 min
and collected. Lysated cells were sonicated four times for 5 min
and centrifuged at 14,000 × g for 10 min. The supernatants were
used for further analysis.
TransAM ELISA for NF-κB Activity
NF-κB activity was determined using a commercial ELISA
kit (TransAM R© NF-κB p65, active motif, La Hulpe, Belgium)
according to the manufacturer’s instructions. In brief, cell extracts
were added to a 96-well plate in which multiple copies of double
stranded DNA were immobilized. After the binding to DNA,
NF-κB was detected with HRP-linked antibody. Plates were
analyzed using the Infinite M2000 ProTM plate reader (Tecan) at
a wavelength of 450 nm.
Western Blot
Western Blot was performed as described before (Esquivel-Solís
et al., 2009) Protein aliquots (60 µg/well) were loaded on a
discontinuous SDS-PAGE for separation. After blotting proteins
to a PVDF-membrane, the membrane was incubated overnight
FIGURE 2 | Effect of STW5 and STW5 on the cytokine profile of NCM460 cells. Cells were treated with STW5 (left) or STW5-II (right) (10 or 20 µl/ml) for 4 h
prior to induction with the CM (10 ng/ml TNF-α, 5 ng/ml IL-1β, and 10 ng/ml IFN-γ) for 24 h. Supernatants were collected and analyzed by Proteome Profiler R© and
evaluated for Pixel density using ImageJ software.
FIGURE 3 | Dose-dependent effects of STW5, STW5-II, and single plant extracts on cytokine release. NCM460 cells were treated with STW5 or STW5-II
(1; 5; 10; 20 µl/ml) or single plant extract (percentage of STW5-II calculated for 10 µl/ml according to content in herbal preparation) for 4 h prior to induction with the
CM (10 ng/ml TNF-α, 5 ng/ml IL-1β, and 10 ng/ml IFN-γ) for 24 h. Supernatants were collected and analyzed by ELISA. # denotes statistical significance at p < 0.05
vs. control, ∗ denotes statistical significance at p < 0.05 vs. sham.
Frontiers in Pharmacology | www.frontiersin.org 4 October 2016 | Volume 7 | Article 393
fphar-07-00393 October 24, 2016 Time: 15:44 # 5
Schneider et al. Anti-inflammatory Effects of Herbal Preparations
with primary antibody; anti-pSTAT1, anti-actin (New England
Biolabs). After washing with TBST, membranes were incubated
for 1 h with secondary HRP-linked antibody. Before the proteins
were detected with LuminataTM Classico Western HRP substrate,
the membrane was washed again three times for 5 min with
TBST. Documentation of the membranes was performed with
ImageJ2 v 2.0 Snap 1.49d software (NIH, Bethesda, MD, USA).
AP-1 Reporter Assay
NCM460 cells were transfected with signal AP-1 reporter
kit (Qiagen) according to manufacturer’s instructions. In
brief, cells were suspended and added to a mixture of
reporter and transfection reagent. After 24 h of transfection,
medium was changed to assay medium (Opti-MEM + 0.5%
FBS + 0.1mM NEAA + 1 mM Sodium pyruvate + 100 U/ml
penicillin+ 100 µg/ml streptomycin) and cells were treated with
10 ng/ml of PMA or CM in mentioned concentrations. PMA
is a known inducer of AP-1 activity and was used as a positive
control. The AP-1 reporter contains a mixture of inducible
AP-1-responsive firefly luciferase construct and constitutively
expressing renilla luciferase construct (40:1). The assay was
developed by using Dual-Luciferase Reporter Assay System
from Promega. Cells were lysed within the wells and luciferase
assay reagent was added. Luminescence was measured on an
Infinite M2000 ProTM plate reader (Tecan). After measuring
firefly luciferase activity, the stop solution was added and the
measurement was repeated to measure renilla luciferase activity.
Relative Luciferase activity was determined as luminescence
signal of firefly luciferase activity normalized to the signal of
renilla luciferase activity.
FIGURE 4 | Effects of STW5 and STW5-II on NF-κB activity: The upper panel displays the NF-κB activity measured by Quanti Blue assay in HEK
reporter cells. The lower panel shows the level of activated NF-κB in NCM460 cell extracts. # denotes statistical significance at p < 0.05 vs. control, ∗ denotes
statistical significance at p < 0.05 vs. sham.
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MAPK p38 Activity Assay
MAPK p38 activity assay was performed as described before
(Huang et al., 1999). NCM460 cells were seeded at 20.000
cells/cm2 in 6-well plates and grown for 3 days before treatment.
For kinetic measurements, cells were treated with the CM for
different periods. For evaluation of STW5 and STW5-II effects,
cells were preincubated with the combination preparations for
4 h before adding the CM. Lysed cells were incubated overnight
with immobilized anti-pp38 antibody beads. Kinase assays were
performed by incubating the immunoprecipitates with ATF-2
fusion protein and ATP for 30 min at 30◦C. The pATF-2 content
was determined by western blot.
RESULTS
Cytotoxicity of STW5 and STW5-II
Both STW5 and STW5-II did not show cytotoxic effects in
a concentration of up to 20 µl/ml (Figure 1). For further
experiments, only non-cytotoxic concentrations were used.
STW5 Inhibited Cytokine Release in a
Dose-Dependent Manner
Cytokine-challenged NCM460 cells showed elevated levels of IL-
8, IP-10, MCP-1, and I-TAC. Treatment with both STW5 and
STW5-II led to significantly reduced cytokine levels compared to
inflamed control as shown by Proteome Profiler. IP-10 showed
the highest induction after cytokine treatment. IL-8, MCP-
1, and I-TAC were most effectively reduced by STW5 and
STW5-II. These four chemokines were chosen for quantitative
examination. ELISA analyses revealed dose-dependent effects of
STW5 and STW5-II. Inhibition of I-TAC and MCP-1 secretion
was most effective and could be reduced at high doses to the level
of untreated cells. Due to the quantitative nature of the ELISA,
STW5-II showed a dose-dependent effect over 1–20 µl/ml, which
was not seen in the Proteome Profiler (Figure 2). The single plant
extracts showed much weaker effects than the two combination
preparations (Figure 3).
Effect on NF-κB Activation
Cytokine-stimulated NCM460 and HEK Blue Null1 reporter cells
showed increased NF-κB activity compared to non-stimulated
control cells (sham). The levels of activated NF-κB were slightly
reduced by both extract combinations (Figure 4).
Effect of Cytokine Mixture on AP-1
Activation
Cells transfected with an AP-1 reporter plasmid showed increased
luciferase activity. Treatment with inflammatory cytokines
reduced the signal (Figure 5), rather than increasing it, and
therefore did not lead to AP-1 activation. The reporter was also
tested with PMA, a standard inducer of AP-1, which led to a
marked increase in luciferase activity.
Effect on MAPK p38
The activity of p38 was determined at different time points after
cytokine treatment. It was five times more active after 10 min
compared to the untreated control (Figure 6). Longer incubation
times led to reduced activities. Pretreatment with STW5 or
STW5-II did not alter the activity (Figure 7).
Effect on STAT1
Cytokine treatment led to an increased phosphorylation of
STAT1 protein compared to non-treated normal controls.
Treatment with STW5-II or STW5 reversed this effect in a dose-
dependent manner. STW5-II was slightly more effective than
FIGURE 5 | Effect of the CM on AP-1 activity: NCM460 cells were transfected with luciferase plasmid under the control of AP-1. Cells were treated with
PMA (10 ng/ml) or the CM (10 ng/ml TNF-α, 5 ng/ml IL-1β, and 10 ng/ml IFN-γ) for 24 h. Cell lysates were analyzed for luciferase activity.
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FIGURE 6 | Effects of STW5 and STW5-II on p38 activity NCM460 cells were treated with the CM (10 ng/ml TNF-α, 5 ng/ml IL-1β, and 10 ng/ml IFN-γ)
for the indicated time points prior to harvesting and p38 activity measurement by ATF-2 phosphorylation. The upper panel shows a representative
western blot for pATF-2. The lower panel displays the quantification of three independent western blot experiments (pixel density fold change compared to 0 min;
three independent experiments; ∗ denotes statistical significance at p < 0.05 vs. 0 min).
FIGURE 7 | Effects of single plant extracts on p38 activity: NCM460 cells were treated with STW5-II or STW5 at 20 µl/ml for 1 h prior to induction with
the CM (10 ng/ml TNF-α, 5 ng/ml IL-1β, and 10 ng/ml IFN-γ) for the indicated time points. Cell lysates were used to measure p38 activity by ATF-2
phosphorylation (pixel density fold change compared to 0 min medium treatment; three independent experiments; ∗ denotes statistical significance at p < 0.05 vs.
medium treatment at the same induction time).
STW5 (Figure 8). None of the single extracts was able to mimic
these effects.
Statistical Analysis
Results are represented as mean± SEM. P-values were calculated
by Student’s t-test. Differences were considered as significant at
P < 0.05.
DISCUSSION
STW5 (Iberogast R©) was shown to be effective in a TNBS model of
intestinal inflammation via Adenosine A2A receptor activation,
and hence inhibition of the TNF-alpha pathway. Furthermore,
STW5 increased IL-10 levels in mucosal preparations of mice
and reduced TNF-α secretion in LPS-induced human monocytes
(Michael et al., 2009, 2012). In a DSS model of inflammation
STW5 was able to reduce biochemical markers and attenuated
histological parameters. Nevertheless, its influence on the
epithelial cells and their contribution to the inflammation process
has yet to be investigated.
In the present study, we have evaluated the effects of
the clinically established fixed combination preparation
STW5 (Iberogast R©) and the modified STW5-II extract
combination, which contains only six of the nine herbal
extracts in STW5, for their immunomodulatory effects on
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FIGURE 8 | Effect of STW5, STW5-II, and single plant extracts on Stat1 phosphorylation: NCM460 cells were treated with STW5 or STW5-II at
indicated concentrations or single plant extract (percentage of STW5-II calculated for 10 µl/ml according to content in the herbal preparation) for 4 h
prior to induction with the CM (10 ng/ml TNF-α, 5 ng/ml IL-1β, and 10 ng/ml IFN-γ) for 30 min. Cell extracts were analyzed for phosphorylated Stat1 protein
by western blotting. The lower panel displays the ratio of pStat1 to actin in relation to the control sample (n = three independent experiments; # denotes statistical
significance at p < 0.05 vs. control, ∗ denotes statistical significance at p < 0.05 vs. sham).
human colonic epithelial cells and the underlying molecular
mechanisms.
Cell models can be used to mimic an inflammatory state
usually by treating the cells with an appropriate stimulus
(Romier-Crouzet et al., 2009; Fernandes et al., 2016). To avoid
artifacts, we used the normal human colon cell line NCM460
(Moyer et al., 1996) rather than colon cancer cell lines. Therefore,
we examined whether NCM460 is responsive to stimuli and
useful as a model of inflammation. As inflammatory stimulus,
a CM consisting of TNF-α, IL-1β, and IFN-γ was used.
These cytokines are known to be released in IBD (Beck and
Wallace, 1997; Ciccia et al., 2012) and are effective in inducing
inflammatory reactions in cell models (Mueller et al., 2013). First,
we profiled the cytokine release of the cells by a membrane-based
sandwich immunoassay. NCM460 cells were able to respond and
secrete a variety of chemokines, some of which are known to
be involved in chemotaxis and were linked to IBD. We decided
to focus on IL-8; MCP-1; I-TAC, and IP-10, as those were the
ones most strongly modulated in our experimental setting. IL-
8 is a powerful neutrophil chemoattractant and activator, whose
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levels are increased in the mucosa of IBD patients (Mitsuyama
et al., 1994). It is also an established inflammatory marker in
other cell lines (Ren et al., 2014; Akbari et al., 2015; Noh et al.,
2015). Levels of MCP-1 were shown to be increased in IBD
(Banks et al., 2003) and were associated with the response toward
infliximab therapy (Magnusson et al., 2015). I-TAC facilitates the
development of Th17 cells and stimulates Th1 cells to produce
IL-6 (Liu et al., 2011). Human intestinal cell lines were shown to
produce I-TAC after cytokine stimulation (Marion et al., 2004).
IP-10 plays a role in the inflammatory process, as it was shown
to be increased in mucosal biopsies from patients with UC or
CD (Ostvik et al., 2013) and was induced in vitro after IFN-γ
stimulation in epithelial cell lines (Dwinell et al., 2001; Marion
et al., 2004). It also presents a promising target for treatment
of IBD, as a phase II study demonstrated efficacy of anti-IP-
10 antibodies in patients suffering from moderate to severe UC
(Mayer et al., 2014).
To investigate a dose-effect relationship, we tested the effect
of the herbal preparations on chemokine release via ELISA.
STW5 was able to reduce IL-8 in a dose-dependent manner,
while STW5-II pretreatment led to an increased secretion at low
concentrations and decreased release at higher ones. C. majus L.
(STW5 KIX) was the only single extract that significantly reduced
IL-8 levels. MCP-1 release from colon cells was significantly
reduced after pretreatment with both STW5 and STW5-II.
Furthermore, almost all single extracts except for G. glabra L.
(STW5 KIV) decreased the secretion of MCP-1 significantly,
but not as effectively as STW5 or STW5-II. Both combination
preparations reduced the cytokine induced IP-10 secretion. Here
STW5-II was a lot more effective than STW5. Interestingly,
STW5-II showed dose-dependent effects on the IP-10 release over
1–20 µg/ml, but no great difference between 5 and 10 µg/ml
and an immense decrease between 10 and 20 µg/ml. This
inconsistency indicates further mechanisms of IP-10 inhibition
which occurs only in high doses of STW5-II. All single extracts
inhibited IP-10 release comparable to STW5 but not to STW5-II.
The secretion of I-TAC was inhibited dose-dependently over 1–
20 µg/ml for both extract combinations. Again, chemokine levels
were stable over 5–10 µg/ml for STW5-II, supporting the theory
of various mechanisms involved in the inhibition.
To examine which signaling pathway might be involved in the
anti-inflammatory mechanism of STW5 and STW5-II, we first
identified molecules that are affected by the cytokine treatment.
Since we used TNF-α, IL-1β, and IFN-γ as stimuli, activated
pathways should lead to the activation of transcription factors like
AP-1, NF-κB, and STAT proteins. Activation of the IL-1β receptor
(IL-1R) or the TNF-α receptor (TNFR) results in recruitment
of adaptor proteins which in turn activate secondary proteins.
The mitogen-activated protein kinase kinase 3 (MEKK3) is a
central kinase in both receptor signaling pathways and is able to
activate the MAPKs p38 and c-Jun NH(2)-terminal kinase (JNK;
Chen and Goeddel, 2002; Wajant et al., 2003). JNK subsequently
activates the transcription factor AP-1 (Weston and Davis, 2002).
MEKK3 also plays a pivotal role in activating the IκB kinase [IKK,
a kinase that phosphorylates the Inhibitor of kappa B (IκB) and
thus causes its degradation and subsequent activation of NF-κB].
Other adaptor proteins in the TNF-α signaling pathway also lead
to activation of IKK. Activation of the IFN-γ receptor results in
the activation of STAT proteins (Ramana et al., 2015). We decided
to focus on these key points in the signaling pathways (Figure 9)
to gain insights in the molecular mechanisms of STW5. Most
of the investigated proteins were shown to be involved in IBD.
FIGURE 9 | Signaling pathways of TNF-α, IL-1β, and IFN-γ: The picture shows a simplified representation of the involved pathways. Recruitment and
activation of adaptor proteins lead to the activation of Transcription factors. STW5 and STW5-II reduced the phosphorylation of Stat1.
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The MAPK p38 is a key regulator in the activation process of
different transcription factors (Chen and Goeddel, 2002; Liacini
et al., 2002; Delgado, 2003).
AP-1 regulates cell responses to a variety of stimuli including
cytokines (Hess et al., 2004). Because AP-1 was previously shown
to be involved in IL-8 release in vivo and in vitro (Moriyama et al.,
2008; Grbic et al., 2012), we examined if AP-1 is also induced
with the CM in our experimental setting. The CM was not able to
increase the activity of AP-1, indicating that it is not responsible
for the cytokine release.
NF-κB is a central transcription factor involved in many
cell functions including the regulation of cytokine expression.
Cytokines found to be involved in IBD like IL-8 are influenced
by NF-κB. Inhibition of the latter was shown to attenuate
signs of experimental colitis in mice (Neurath et al., 1996).
To determine the activity of NF-κB in NCM460 cells, protein
extracts were added to plates in which multiple copies of
double stranded consensus DNA were immobilized. Induction
of NF-κB was insufficient in this setting, but the results
hinted to some activity of STW5 and previous literature data
showed a potent effect on NF-κB in colon adenocarcinoma
cells (Bonaterra et al., 2013). Therefore, we further examined
the influence of cytokines and extract in commercial available
HEK-BlueTM Null1 cells which express the SEAP (secreted
alkaline phosphatase) reporter gene under the control of the
IFN-β minimal promoter fused to five NF-κB and AP-1
binding sites. In these cells, NF-κB activity was sufficiently
increased after cytokine treatment. Nevertheless, STW5 and
STW5-II had only week effects, not sufficient to explain the
inhibition of cytokine release. We concluded that NF-κB activity
is not affected by the plant extract combinations in our
model.
p38 mitogen-activated protein kinase (MAPK) signaling
pathways were shown to be involved in IBD and can be
induced by inflammatory cytokines like IL-1β and TNF-α (Feng
and Li, 2011). Furthermore, p38 is involved in the activation
of transcription factors. To measure the activation of p38,
protein extracts were precipitated with immobilized anti-pp38
antibody beads. Activity was measured by the ability of p38 to
phosphorylate ATF-2. As expected, the treatment with cytokines
increased the activity of p38 which peaked after 10 min induction
time. Pretreatment with the extract combinations showed no
effect at all during the activation of p38. This indicates that p38
is not affected by STW5 or STW5-II.
STAT proteins are cytoplasmic transcription factors, which
dimerize and translocate to the nucleus upon phosphorylation,
where they interact with DNA and induce transcription. STAT1
protein expression and phosphorylation were increased in
mucosal samples from IBD patients (Schreiber et al., 2002). Also,
increased phosphorylation of STAT1 was observed in cell models
of IBD (Li et al., 2012; Wang et al., 2012). STAT1 phosphorylation
can be induced by IFN-γ, making STAT1 a possible target of
the plant extract combinations. We showed that pSTAT1 levels
increased after cytokine treatment. Furthermore, pretreatment
with STW5 or STW5-II revealed a dose-dependent inhibition
over 1–20 µg/ml. STAT3 and STAT5 were also inhibited by the
combination preparation. However, their induction was rather
week in our experimental setting, therefore their contribution to
the overall inflammatory state is probably minor.
Thus, inhibiting STAT1 might explain the reduced cytokine
expression, which in turn could partly explain the anti-
inflammatory effects of STW5 and STW5-II.
CONCLUSION
Human epithelial cells react to inflammatory stimuli (e.g., Th1
cytokines) by releasing a subset of chemokines, which in turn
attract immune cells such as macrophages. Our study revealed
that the herbal preparation STW5 (Iberogast R©) and the modified
investigational combination STW5-II reversed these effects
without affecting NF-κB activity. Further studies showed that
the extract combinations reduced STAT1 phosphorylation. We
conclude that these herbal preparations may have a therapeutic
potential for patients with IBD.
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